Chapman University

Chapman University Digital Commons
Pharmacy Faculty Articles and Research

School of Pharmacy

2012

Anti-Platelet Therapy in Acute Coronary
Syndromes: Updates in Therapy After Stent
Implantation
Ryan McKenzie
Midwestern University

Andrew Park
Midwestern University

Laura Tsu
Chapman University, ltsu@chapman.edu

Follow this and additional works at: http://digitalcommons.chapman.edu/pharmacy_articles
Part of the Cardiovascular Diseases Commons, Medical Education Commons, Other Pharmacy
and Pharmaceutical Sciences Commons, and the Science and Mathematics Education Commons
Recommended Citation
McKenzie R, Park A, Tsu LV. Anti-platelet therapy in acute coronary syndromes: Updates in therapy after stent implantation. Arizona
Journal of Pharmacy 2012;33-40.

This Article is brought to you for free and open access by the School of Pharmacy at Chapman University Digital Commons. It has been accepted for
inclusion in Pharmacy Faculty Articles and Research by an authorized administrator of Chapman University Digital Commons. For more information,
please contact laughtin@chapman.edu.

Anti-Platelet Therapy in Acute Coronary Syndromes: Updates in Therapy
After Stent Implantation
Comments

This article was originally published in Arizona Journal of Pharmacy in 2012. Those receiving articles through
Chapman University Digital Commons may not receive Continuing Education (CE) credit.
Copyright

Arizona Journal of Pharmacy. All rights reserved. This publication may not be republished or re-distributed
without authorization from the Arizona Pharmacy Association.

This article is available at Chapman University Digital Commons: http://digitalcommons.chapman.edu/pharmacy_articles/217

Continuing Education

Anti-platelet Therapy in Acute Coronary Syndromes: Updates in Therapy
after Stent Implantation

by Ryun McKenzie, Pharm.D. Candidate Class of 2013; Andrew Park, Pharm.D. Candidate Class of 2013; Laura Tsu, Pharm.D.,
BCPS; Midwestern University College of Pharmacy - Glendale
stent restenosis and in-stent thrombosis.
the use of aspirin therapy with a P2Y12
Goal:
Anti-platelet therapy for secondary
This home-study CPE activity has been
receptor antagonist post-cardiac stent
developed to educate pharmacists on
prevention of cardiac events in the first
implantation. In contrast, the guidelines
updates in anti-platelet therapy after stent
year after ACS with PCI therapy and stent
differ with regard to the preference
implantation.
placement centers on several options:
given to the individual P2Y12 receptor
clopidogrel, prasugrel, ticagrelor, and
antagonist. The recent CHEST guidelines
Objectives:
aspirin. The first 3 agents are P2Y12
give preference to ticagrelor therapy over
At the conclusion of this lesson, successful receptor antagonists while aspirin inhibits
clopidogrel and prasugrel.2,4 Therefore,
participants should be able to:
platelet cyclooxygenase-1. Regardless of
the focus of this review is to compare the
1. Identify the mechanism of action and
the mechanism, inhibition of these platelet similarities and differences in efficacy
unique characteristics of the FDApathways ultimately results in decreased
and safety between the 3 FDA-approved
approved P2Y12 receptor antagonists
platelet activation and aggregation.
P2Y12 receptor antagonist: clopidogrel,
used in secondary prevention of
For patients with implanted coronary
prasgurel, and ticagrelor.
cardiovascular disease.
stents, there are differing lengths of
2. Describe the recent recommendations
anti-platelet therapy based on the type
Clopidogrel (Plavix®)
2,3
Clopidogrel is a second-generation
regarding safety and efficacy for oral
of stent placed. The recommended
thienopyridine which irreversibly
anti-platelet therapy post cardiac-stent therapy for bare metal stent placement
include dual anti-platelet therapy with
inhibits the P2Y12 receptor on platelets.
placement.
aspirin 75 - 325 mg daily and clopidogrel
It is a pro-drug that requires hepatic
3. Compare the benefits and risks
75 mg for 1 month, then low dose aspirin
biotransformation via CYP enzymes,
associated with each P2Y12 receptor
antagonists based on presented
81 mg daily and clopidogrel 75 mg daily
particularly CYP2C19, to produce the
clinical data.
for the subsequent 11 months, and then
active metabolite necessary to exert its
4. Select the appropriate anti-platelet
single anti-platelet therapy with aspirin
pharmacological actions.5 The active
therapy using patient-specific
81 mg daily indefinitely thereafter. The
metabolite formed in this process
parameters for prevention of recurrent recommended therapy for drug-eluting
targets the P2Y12 receptor, one of the
cardiac events.
stent placement include dual anti-platelet
adenosine diphosphate (ADP) receptors
therapy with aspirin 75 - 325 mg with
on the platelet surface, to prevent platelet
clopidogrel 75 mg daily for 3 - 6 months
Introduction
recruitment and activation of the GPIIb/
(minimum of 3 months for sirolimusDespite advances in pharmacotherapy
IIIa receptor complex; in so doing, platelet
and technology, acute coronary syndromes eluting stent and 6 months for paclitaxelaggregation is reduced.6 Clopidogrel’s
(ACS) remains a significant healthcare
eluting stent), then low dose aspirin
pharmacokinetic profile exhibits rapid
issue with more than 1.2 million
with clopidogrel 75 mg daily for 6 - 9
dose absorption with or without food.7
Americans suffering an ACS event
months thereafter, and then single antiThe conversion of the parent drug to
annually.1 The usual culprit in ACS is an
platelet therapy with aspirin 81 mg daily
active metabolite with maintenance
atheromatous plaque rupture which causes indefinitely (see Figure 1. for algorithm).4
dosing at 75 mg daily takes, on average,
platelet activation and aggregation, leading The 2011 American College of Cardiology about two days to see inhibition of
to the propagation of the coagulation
Foundation/American Heart Association
platelet aggregation (IPA) with peak
cascade. If untreated, the formation of a
Task force on Practice Guidelines and the
effect occurring in 5 - 7 days.8 Due to
the potential need for rapid inhibition of
platelet-rich “white” clot will lead to an
Society for Cardiovascular Angiography
platelet aggregation, loading doses have
ACS event, which includes ST segment
and Interventions (ACCF/AHA/SCAI)
been used to achieve faster therapeutic
elevation myocardial infarction (STEMI),
recommend indefinite aspirin 81 mg
goals as studies have shown that peak IPA
non-ST segment elevation myocardial
therapy in preference over higher doses
was able to be achieved within 6 hours
infarction (NSTEMI) or unstable angina
in combination with P2Y12 receptor
antagonists. A minimum of 12 months of
with higher loading doses (300 mg, 600
(UA). Treatment options for ACS include
percutaneous coronary interventions (PCI) therapy with P2Y12 receptor antagonists
mg, 900 mg).9
with stent implantation, thrombolytic
is recommended with either a bare metal
Although approximately half of the
therapy, and/or medical management.
stent or drug-eluting stent if the patient is
systemically circulating clopidogrel is
After the acute treatment of patients
not at high risk of bleeding. Continuation
cleared through the kidneys and the other
with ACS, the pharmacotherapy focus
of therapy beyond 12 months may be
half in the feces, there is limited data
shifts to secondary prevention of
considered for those with drug-eluting
on the safety of this medication in renal
cardiovascular events. In patients who
stent placement and low risk of bleeding
impairment. No adjustment is necessary
receive a stent implantation, one of the
(see Figure 2. for algorithm).2
for those with hepatic impairment. It
most important preventative measures
Both the CHEST and 2011 ACCF/AHA/ is also important to consider that while
is anti-platelet therapy to prevent both
SCAI practice guidelines recommend
the half-life of clopidogrel is relatively
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short (~ 0.5 hour) compared to the
parent compound (~ 6 hours), it binds
irreversibly to the platelet receptors
resulting in normal platelet function of
those blocked by clopidogrel to return
with the development of new platelets.
Platelet turnover takes approximately 7-10
days which is how long it would take for
normal platelet function to return after the
last dose of clopidogrel is administered.4,7
Efficacy of clopidogrel in PCI
For patients with newly placed coronary
stents, dual anti-platelet therapy with
clopidogrel in addition to aspirin has
shown to improve outcomes with longterm therapy. Data from studies such
as the PCI-CURE trial which found
significantly lower rates of cardiovascular
(CV) death, myocardial infarction (MI),
or any revascularization in patients
undergone PCI with dual anti-platelet
therapy beyond 4 weeks of treatment
have helped to focus subsequent studies
on the optimal length of therapy.10 The
CREDO trial did just that and provided
optimization for long-term anti-platelet
therapy post-PCI when they found that
there was relative reduction (26.9%)
in combined CV events with at least
a year of long-term dual therapy with
clopidogrel and aspirin.11 These trials
highlight the significant use of clopidogrel
in this patient population; however, the
following sections will address several
considerations that should be made when
choosing this agent.
Drug Interactions with Proton Pump
Inhibitors
In an effort to maintain high therapeutic
efficacy but minimize gastrointestinal (GI)
toxicity from clopidogrel use, clinicians
began adding on proton-pump inhibitor
(PPI) treatment. While effective, in vitro
data supported the notion that competitive
inhibition by PPIs of CYP2C19 may
alter the necessary metabolic step
needed to produce the active metabolite
of clopidogrel.12 The focus of current
discussion is the therapeutic effect this
interaction has on therapy outcomes. In
the prospective randomized placebocontrolled COGENT trial of 3,873
patients, investigators assigned patients
on dual anti-platelet therapy (clopidogrel
75 mg and aspirin 75 mg - 325 mg daily)
to either omeprazole 20 mg or placebo.
The primary endpoint of composite
gastrointestinal event as determined by

bleeding ulcers, obstruction, or perforation
addressed the potential benefits of
gastrointestinal protection while on antiplatelet therapy. In addition, the primary
safety endpoint composite of CV events
as determined by death from CV causes,
MI, revascularization, or stroke addressed
the proposed interaction between
clopidogrel and omeprazole on decreased
anti-platelet activity. The study found
lower gastrointestinal events rates with
omeprazole when compared to placebo;
supportively, in the safety endpoint
comparison, there was no difference in the
risk of CV events or MI in the treatment
groups.13
In order to evaluate the effects of this
interaction even further, a meta-analysis
of twenty five studies (159,138 patients)
was performed to assess the association
of adverse events with combination
therapy. They found that combination
therapy with PPIs (searched keywords
of ‘pantoprazole,’ or ‘omeprazole’ or
‘esomeprazole’ or ‘lansoprazole’ or
‘rabeprazole’) with clopidogrel was
associated with increased risks of major
adverse CV events and MI at 29%
and 31%, respectively. However, PPI
use was not associated with an overall
increase in mortality. Subgroup analyses
of concomitant use of clopidogrel with
either pantoprazole or omeprazole were
not associated with an increased risk of
major CV events. While the analysis
showed no influence on mortality, the
investigators did find a decrease in the
risk of developing GI bleed under PPI
treatment by 50%.12
In lieu of the results presented in these
trials, the Food and Drug Administration
continues to warn against concomitant use
of clopidogrel and PPIs, and recommends
that combination treatment be used
with caution. It should be noted that
this warning advisory does not apply to
all PPIs as not all PPIs affect the CYP
enzymes similarly.14 The ACCF/ACG/
AHA released a 2010 update on the 2008
Expert Consensus Document on Reducing
the Gastrointestinal Risks of Antiplatelet
Therapy and NSAID Use stating that a
small to moderate association can be made
based on available evidence; however,
further randomized controlled trials
are needed to validate the associations
found in observational studies. While
several trials showed no significant
association of CV events, the potential
relative risk of CV events may warrant
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caution in combination therapy. The lack
of consensus among trials confounds
a clear association of PPI use with
clopidogrel as the data is weak to establish
decreased anti-platelet activity with
coadministration. Ultimately, treatment
decisions need to assess whether the
potential benefits outweighs potential
harm as patients with prior upper GI
bleeding and risk factors may benefit from
prophylaxis against GI bleeding.15
Decreased platelet responsiveness
In regards to anti-platelet efficacy,
clopidogrel has a black box warning
notifying that patients with genetic
variability in CYP2C19 function,
such as those with two nonfunctional
alleles termed “poor metabolizers” of
clopidogrel, may have reduced antiplatelet activity. Studies have suggested
that high on-treatment platelet reactivity,
those that require higher doses to achieve
therapeutic effect, occurs in onethird of those prescribed clopidogrel.4
As a result, there have been higher
cardiovascular event rates when this
patient population is exposed to normal
recommended doses when compared
to those that do not have the decreased
CYP2C19 function. A meta-analysis
compared the risk of major adverse
cardiovascular events of clopidogrel
administration between noncarriers
(71.5%), heterozygotes (26.3%), or
homozygotes (2.2%) of reduced-function
CYP2C19 alleles that underwent PCI
that had an ACS. This study found that
there was a significantly increased risk
in both the patient populations with 1
reduced-function CYP2C19 allele and 2
reduced-function CYP2C19 alleles when
compared to noncarriers. The analysis
also found a significantly increased risk
of stent thrombosis in both carriers of the
reduced-function allele suggesting those
patient populations with even 1 reducedfunction CYP2C19 allele may not be
fully protected from cardiovascular events
despite standard doses of clopidogrel.16
Considering this patient population, there
currently lacks support for the use genetic
testing or platelet function testing to
individualize anti-platelet therapy.3
Dosing and monitoring of clopidogrel
Clopidogrel is recommended to be
administered as a 600 mg loading dose
during PCI, followed by 75 mg daily
maintenance dose.2 In addition to the
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aforementioned precautions regarding
PPIs, healthcare providers should be aware
of other medications that are CYP2C19
inhibitors. Examples include fluconazole,
voriconazole, and fluoxetine.
As with other medications in the
thienopyridine class, there are risks
of bleeding present with clopidogrel.
Careful consideration in certain
patient populations should be made
as clopidogrel is contraindicated in
those with active bleeding such as
peptic ulcer or intracranial hemorrhage.
Bleeding concerns have also prompted
the recommendation to discontinue
clopidogrel 5 days prior to surgery.
When clopidogrel was stopped beyond
5 days before a coronary artery bypass
graft (CABG), rates of major bleeding
were similar to those taking placebo. In
comparison, patients who remained on
clopidogrel within 5 days of a CABG,
rates of major bleeding were higher at
9.3% compared to 6.3% in the placebo
group (see Table 1 for comparison chart).17
Newer anticoagulants options:
prasugrel and ticagrelor
Clopidogrel has been clinically proven
to reduce recurrent cardiovascular
events but clopidogrel has several
limitations: it is a pro-drug that requires
hepatic conversion, has a delayed onset,
and demonstrates a wide inter-patient
variability and delayed recovery due to
irreversible receptor binding. Prasugrel
and ticagrelor, two relatively new P2Y12
receptor antagonists have been approved
as alternatives to clopidogrel for patients
with ACS undergoing PCI with stent
placement.2,4 Both seek to address some
of the issues faced with clopidogrel.
Prasugrel (Effient®)
Prasugrel was approved in 2009 for
the reduction of recurrent cardiovascular
events in patients with ACS who are
undergoing PCI. Similar to clopidogrel,
prasugrel is a thienopyridine which
irreversibly inhibits the P2Y12 receptor on
the platelet.18 Prasugrel seeks to improve
upon the shortcomings of clopidogrel
with some key differences. While it is
also a pro-drug, prasugrel is metabolized
in the gastrointestinal tract and liver
more rapidly than clopidogrel and the
resulting metabolite binds irreversibly to
the P2Y12 receptors on platelets inhibiting
their aggregation without the need for a
second activation step compared to two

for clopidogrel. Also, prasugrel is not as
adversely affected by individual genetic
variations, which results in faster and
more predictable platelet inhibition.5 It
can reach peak concentration in as quickly
as 30 minutes and last up to 7 hours.19
Efficacy and safety of prasugrel
The TRITON-TIMI 38 phase 3 study
sought to determine the safety and efficacy
of prasugrel compared to clopidogrel
in 13, 608 patients with ACS who were
undergoing PCI. Clopidogrel was
administered as a 300 mg loading dose
then 75 mg daily while the comparator
group was administered prasugrel 60 mg
loading dose then 10 mg daily for 6 to 15
months. The study measured the primary
efficacy endpoints of death from CV
causes, nonfatal MI, and nonfatal stroke,
while the incidence of major bleeding
was the major safety endpoint. It was
observed that in addition to a significantly
lower number of primary efficacy
endpoint events with prasugrel (9.9%) as
compared with clopidogrel (12.1%), the
prasugrel group also had fewer rates of
MI, target-vessel revascularization, and
stent thrombosis. However, the added
benefit of increased efficacy came with the
drawback of a higher incidence of major
and life-threatening bleeding events in the
prasugrel group.20
Due to this increased risk of bleeding
in the total study population, further
subgroup analyses were performed to
determine whether or not certain patient
populations would experience a greater
net clinical benefit from prasugrel, with
the reduction in cardiovascular events
outweighing the bleeding risk. To answer
these questions, 2 separate subgroup
analyses were performed on patients
with diabetes and with a STEMI. Of the
total 13,608 patients in the TRITONTIMI 38 trial, the first subgroup analysis
trial explored the safety and efficacy of
prasugrel versus clopidogrel in the 3,146
patients with diabetes mellitus (DM).
From a primary efficacy standpoint, there
were significantly fewer incidents of (CV
death, non-fatal MI, or non-fatal stroke)
with prasugrel compared to clopidogrel in
both the diabetic (9.2% versus 10.6%) and
non-diabetic (12.2% versus 17%) groups.
In contrast to the findings in the original
TRITON-TIMI 38 trial, the diabetic
subgroup in this study did not have an
increased risk of major bleeding compared
to clopidogrel (2.6% versus 2.5%). For

patients on prasugrel, the greater relative
reduction in incidents of the primary end
point and MI events without an observed
increase in major bleeding provided a
greater net clinical benefit when compared
to clopidogrel.21
The other subgroup analysis included
3,534 participants with STEMI treated
with either prasugrel or clopidogrel. The
primary endpoint was a composite of CV
death, non-fatal MI, or non-fatal stroke
at 30 days and at 15 months. Compared
to clopidogrel, the prasugrel group had
a significantly lower incidence of the
primary efficacy endpoint at both 30 days
(9.5% vs. 6.5%) and at 15 months (12.4%
vs. 10%). There was no significant
difference in major bleeding unrelated
to CABG surgery between both groups;
similarly, no difference was reported in
life-threatening bleeding, intracranial
hemorrhage, or minor bleeding at 15
months. However, it was observed that
patients on prasugrel who underwent
CABG surgery experienced an increased
risk for major bleeding compared to those
on clopidogrel.22 Therefore, STEMI
patients may also be a population in
which prasugrel demonstrates a greater
net clinical benefit when compared to
clopidogrel.
Although prasugrel showed additional
benefits for diabetics and those who
have STEMIs, it is important to note
that neither of these subgroup analyses
were designed or powered for all clinical
endpoints in the population, and the
small sample size may have skewed the
results.21, 22
Dosing and monitoring of prasugrel
In patients undergoing PCI with
stent placement, prasugrel is typically
administered as a single 60 mg loading
dose followed by a maintenance dose of
10 mg once daily if the patient weighs
more than 60 kg. Patients with lower
body weights may have an increased risk
of bleeding and it is recommended that a
lower 5 mg maintenance dose be used for
those weighing less than 60 kg.2, 23 It must
be noted, however, that although a lower
maintenance dose is recommended for
lower weight patients, safety and efficacy
at this dose has not yet been studied.
Most of the contraindications and
warnings center on patients with these
risks due to the increased incidence of
major and potentially fatal bleeding seen
in the prasugrel trials when compared
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to clopidogrel. It is contraindicated in
patients with active pathological bleeding,
history of transient ischemic attack (TIA)
or stroke. Other high risk populations
with an increased risk of bleeding include
patients older than 75 years, weigh less
than 60 kg, have a propensity to bleed, and
are using concomitant medications that
increase bleeding risk. Examples of these
medications include warfarin, NSAIDS or
fibrinolytic therapy. While it is generally
not recommended to use prasugrel in
patients older than 75 years, it may be
considered in patients with diabetes or
STEMI, as those groups demonstrated a
greater net clinical benefit compared to the
total study population.21
Prasugrel should be stopped at least
7 days before CABG with the extra
time required due to the longer halflife.21 If possible, it is recommended
that any bleeding be managed without
discontinuing the medication due to
increased risk of cardiovascular events
if stopped prematurely. Practitioners
managing these patients should also
consider other common adverse
drug events, including hypertension,
hyperlipidemia, head and backaches,
dyspnea, nausea and vomiting.
Concomitant use of medications that
increase bleeding risk should be avoided
if possible, but interactions with CYP
inducers or inhibiters were not significant.
Fortunately, there is no renal dosing and
the lower CYP activation means that no
dose adjustment is needed in patients with
mild to moderate hepatic impairment (see
Table 1 for comparison chart).23
Ticagrelor (Brilinta®)
Ticagrelor is classified as a cyclopentyltriazolpyrimidine. It binds reversibly to
the P2Y12 receptor at an allosteric site,
changes the receptor conformation, and
prevents ADP-stimulated activation of
the glycoprotein IIb/IIIa receptor and
attenuating platelet aggregation.5 Unlike
clopidogrel and prasugrel, ticagrelor
is not a pro-drug and does not require
metabolism to an active form. It is also
broken down into at least one active
metabolite with a similar potency to
the parent drug. This combination of
properties produces a rapid onset of action
within 30 minutes, and a peak inhibitory
effect in 2 hours.5
Efficacy and safety of ticagrelor
The landmark phase 3 PLATO trial

compared the safety and efficacy of
ticagrelor with clopidogrel for prevention
of cardiovascular events in patients with
ACS.26 Ticagrelor was given as a 180 mg
loading dose then 90 mg twice daily and
clopidogrel was given as a 300 – 600 mg
loading dose then 75 mg daily. This study
followed 18,624 patients over 12 months
to determine the outcomes for a primary
efficacy end point designated as time to
the first occurrence of a composite of
death from vascular causes, MI or stroke
and primary safety endpoints of first
occurrence of major bleeding.26 It was
observed that ticagrelor (9.8%) showed
greater efficacy in preventing the primary
efficacy end points than clopidogrel
(11.7%) and the incidents of major
bleeding were similar between the two
groups (ticagrelor 11.6% vs. clopidogrel
11.2%). Unfortunately, patients on
ticagrelor did experience a higher rate
of non–CABG-related major bleeding,
intracranial bleeding and dyspnea.26
The PLATO trial discovered an
anomaly in which ticagrelor was
significantly less effective in North
American patients compared to the rest
of the world. The North American substudy sought to determine the possible
causes of this difference, and identified
an underlying statistical interaction with
aspirin maintenance dose. Of the 37
factors explored, only the maintenance
aspirin dose emerged as a possible
explanation for the regional differences.23
Analysis revealed that more patients
in the United States (53.6%) took a
higher maintenance dose of aspirin >
300 mg than the rest of world (1.7%)
and that low-dose maintenance aspirin
concomitantly with ticagrelor had better
outcomes compared to clopidogrel.
The authors of the study theorized that
aspirin’s dose dependent inhibition of
endothelial prostacyclin may reduce the
anti-platelet effect of ticagrelor at higher
doses. However, they do acknowledge
that further research is needed to elucidate
the possible mechanism of this interaction
and that chance cannot be ruled out given
the current data.23 Based on the current
available data, it is recommended that
ticagrelor should only be administered
with low-dose maintenance aspirin.23
Dosing and monitoring of ticagrelor
Patients being started on ticagrelor
should be given an initial loading dose
of 180 mg at the time of PCI, and then
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continued on a maintenance dose of 90
mg twice daily.24 Ticagrelor is primarily
metabolized by hepatic CYP3A4
enzymes so it is susceptible to drug
interactions with medications that inhibit
or induce these enzymes. Concomitant
use of inducers such as rifampin or
phenytoin and inhibitors such as azoles,
clarithromycin or protease inhibitors
should be avoided. Ticagrelor can reduce
the metabolism of other drugs which are
CYP3A4 substrates such as simvastatin,
resulting in a higher serum simvastatin
concentration and an increased risk of
rhabdomyolysis. Serum levels of digoxin,
a medication with a narrow therapeutic
window, must also be monitored closely if
used concomitantly with ticagrelor.24
Due to an increased risk of bleeding,
ticagrelor has a black box warning
cautioning against use in patients with a
history of intracranial hemorrhage and
active bleeding.24 It is also recommended
to discontinue ticagrelor at least 5 days
prior to CABG. It is important to note that
the warning label advises to try managing
bleeding episodes while remaining on
ticagrelor as premature discontinuation
increases the risk of cardiovascular
events. Also included in the black box
warning is the recommendation for use
with aspirin 81 mg for efficacy. It is also
advised against the use in patients with
severe hepatic impairment.24 Dyspnea was
a common adverse effected noted with
ticagrelor, occurring in approximately
14% of patients studied within the first
few weeks after medication initiation.
Other noted adverse events include,
asymptomatic bradycardia, and ventricular
pauses.24 There have been reported cases
of increase in uric acid levels as well,
so caution should be taken in patients
with a history of gout (see Table 1 for
comparison chart).
The safety and efficacy of ticagrelor in
elderly patients is of particular concern
because while this population is at
increased risk of cardiac complications,
they are also at higher risks of bleeding.
Fortunately, the PLATO trial did not
identify any difference in safety or
efficacy between younger and older
patients, although it is recommended that
older patients be monitored more carefully
for bleeding complications.
General Considerations: P2Y12 receptor
antagonists
Patients should be counseled on the
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importance of continuing dual anti-platelet
therapy for the full recommended duration
because early discontinuation can result in
recurrent cardiovascular events. Another
important counseling area includes the
increased risk for bleeding and patients
should be taught to be aware of certain
things, such as signs and symptoms
of bleeding (dark colored urine and
stool). These patients will bruise more
easily, and take longer than usual to stop
bleeding. They should promptly report
any unanticipated, prolonged, or excessive
bleeding immediately to their health care
provider.
Pharmacist’s Role
With these newer anti-platelet agents,
pharmacists can play a pivotal role in
both monitoring and educating patients,
whether in hospital, clinic, or community
settings. Each of the agents discussed
may provide enhanced benefit to specific
patient populations. However, they also
come with additional precautions, possible
adverse events and interactions that
must be carefully evaluated along with
patient specific information, evidenced
based research and clinical judgment to
determine the best course of treatment.
These new drugs provide extra tools
in the healthcare provider arsenal for
treating patients undergoing PCI with stent
placement. As the medication experts,
pharmacists are uniquely qualified to help
match up the right drug to the right patient
and ensure optimal treatment outcomes.
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Continuing Education (continued from page 37)
Clopidogrel

Prasugrel

Ticagrelor

Irreversible P2Y12 receptor
antagonist
Pro-drug with 1-step
activation
60 mg

Reversible P2Y12 receptor
antagonist
Active drug

Loading dose

Irreversible P2Y12 receptor
antagonist
Pro-drug with 2-step
activation
300 - 600 mg

Maintenance dose

75 mg QD

10 mg QD

90 mg BID

Inhibition of platelet
aggregation
Renal adjustment

Dose-dependent:
300-600 mg within 6 hours
No

Dose-dependent:
60 mg <30 minutes
No

Dose-dependent:
180 mg <30 minutes
No

Hepatic adjustment

No

No

No

Warnings
/precautions

Reduced 2C19 function
(BBW)

Drug interactions

2C19 inhibitors

History of TIA or stroke
(BBW), age≥75, weight <60
kg
None significant

Use with low dose aspirin
only, history of ICH (both
BBWs)
3A4 inhibitors and inducers

Notes

Hold 5 days prior to CABG

Hold 7 days prior to CABG,
benefits in STEMI and DM

Hold 5 days prior to CABG,
increased dyspnea, moderate
hepatic impairment

Mechanism of action
Activation

Table 1. Comparison of P2Y12 receptor antagonists7,22,24
BBW=Black Box Warning
TIA= Transient ischemic attack
STEMI= ST segment elevation
CABG= Coronary Artery Bypass Grafting
DM=Diabetes Mellitus
ICH=Intracranial hemorrhage

180 mg

Figure 1. Anti-platelet therapy recommendations from ACCP CHEST 2012 practice guidelines4

Clopidogrel
Prasugrel
Patients that have undergone PCI with stent  Patients that have undergone PCI with stent
placement, give dual antiplatelet therapy
placement, give dual antiplatelet therapy
with clopidogrel 75 mg/day and aspirin
with prasugrel 10 mg/day and aspirin
therapy daily (1B)
therapy daily(1B)
 Continue aspirin therapy 75 -325 mg/day:
 Continue aspirin therapy 75 -325 mg/day:
 BMS: 1 month (1A), then 75 – 100
 BMS: 1 month (1A), then 75 – 100
mg/day for 11 months (2C)
mg/day for 11 months (2C)
 Sirolimus-eluting stent: 3 months (1A),
 Sirolimus-eluting stent: 3 months (1A),
then 75 – 100 mg/day until 12 months
then 75 – 100 mg/day until 12 months
(2C)
(2C)
 Paclitaxel-eluting stent: 6 months (1A),
 Paclitaxel-eluting stent: 6 months (1A),
then 75 – 100 mg/day until 12 months
then 75 – 100 mg/day until 12 months
(2C)
(2C)
1A= Strong recommendation, high-quality evidence
1B= Strong recommendation, moderate-quality evidence
2C= Weak recommendation, low-quality or very low-quality evidence
PCI= Percutaneous coronary intervention
BMS = bare metal stent






Ticagrelor
Patients that have undergone PCI with stent
placement, give dual antiplatelet therapy
with ticagrelor 90 mg/BID and aspirin
therapy daily(1B)
Continue aspirin therapy 75 -325 mg/day:
 BMS: 1 month (1A), then 75 – 100
mg/day for 11 months (2C)
 Sirolimus-eluting stent: 3 months (1A),
then 75 – 100 mg/day until 12 months
(2C)
 Paclitaxel-eluting stent: 6 months (1A),
then 75 – 100 mg/day until 12 months
(2C)

Figure 2. Anti-platelet therapy recommendations from 2011 ACCF/AHA/SCAI practice guidelines2

B



B






Prasugrel

Before PCI, give nonenteric aspirin
325 mg
If on previous therapy, continue
aspirin 81 mg to 325 mg
Patients undergoing PCI, add
clopidogrel 600 mg load followed
by 75 mg/day to aspirin therapy then
continue clopidogrel:
 BMS: ≥ 12 months
 DES: ≥ 12 months
After PCI, aspirin should be
continued indefinitely



Dual therapy > 12 months may be
considered



C

Class IIb:
Benefit ≥
Risk

Clopidogrel



A

Class I: Benefit >>>Risk

Evidence
classification

A= Multiple populations evaluated
B= Limited populations evaluated
C= Very limited populations evaluated
PCI= Percutaneous coronary intervention
BMS= Bare metal stent
DES= Drug-eluting stent
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Ticagrelor

Before PCI, give nonenteric aspirin
325 mg
If on previous therapy, continue
aspirin 81 mg to 325 mg
Patients undergoing PCI, add
prasugrel 60 mg load followed by
10 mg/day to aspirin therapy then
continue prasugrel:
 BMS: ≥ 12 months
 DES: ≥ 12 months
After PCI, aspirin should be
continued indefinitely



Dual therapy > 12 months may be
considered








Before PCI: give nonenteric aspirin
325 mg
If on previous therapy, continue
aspirin 81 mg to 325 mg
Patients undergoing PCI, add
ticagrelor 180 mg load followed
by 90 mg/twice a day to aspirin
therapy then continue ticagrelor:
 BMS: ≥ 12 months
 DES: ≥ 12 months
After PCI, aspirin should be
continued indefinitely
Dual therapy > 12 months may be
considered

Continuing Education Quiz
Anti-platelet Therapy in Acute Coronary Syndromes: Updates in Therapy after Stent Implantation
1. Clopidogrel acts primarily by :
a. Stimulating the ADP receptors on the platelet
surface
b. Increasing platelet aggregation via P2Y12
receptors
c. Inhibiting the P2Y12 receptor on platelets
d. None of the above
2. Which of the following statements is correct and
may explain the differences in onset of action of the
3 drugs?
a. Clopidogrel , prasugrel and ticagrelor are all pro
drugs
b. Only clopidogrel is a pro drug. Prasugrel and
ticagrelor are active medications
c. Only ticagrelor is a pro drug. Clopidogrel and
prasugrel are active medications
d. Both clopidogrel and prasugrel are pro drugs.
Ticagrelor is an active medication
3. The black box warning for ticagrelor:
a. Cautions against use in patients with a history of
intracranial hemorrhage and active bleeding
b. Warns that patients with genetic variability in
their CYP2C19 allele may have reduced antiplatelet activity
c. Advises against use in patients ≥ 75 years with
the exception of high risk situations
d. Advises to avoid use in patients with unstable
angina due to increased bleeding risk
4. Which potential drug-drug interaction has
continued warnings because of the potential
increase in cardiovascular events with concomitant
use?
a. Clopidogrel and aspirin
b. Ticagrelor and proton pump inhibitors
c. Prasugrel and aspirin
d. Clopidogrel and proton pump inhibitors

5. What is the minimum length of time for
thromboembolic prophylaxis for PCI patients with
a sirolimus-eluting stent on clopidogrel, ticagrelor
or prasugrel?
a. Patients may be transitioned off prophylaxis after
1 month if they are at low risk for a thromboembolic
event.
b. Treatment should be discontinued immediately
after PCI if the patient is not in a high risk group
c. Treatment should be continued indefinitely
due to the high risk for thromboembolic events
following PCI
d. ost patients should be treated for a minimum of
12 months
6. The North American sub study of ticagrelor
found that:
a. Patients on lower maintenance doses of aspirin
(< 300 mg) concomitantly with ticagrelor had better
outcomes
b. Ticagrelor is best taken on an empty stomach as
higher gastrointestinal pH increases bioavailability
c. Ticagrelor is teratogenic and should be avoided
in patients who are pregnant or planning to become
pregnant within 6 months
d. Ticagrelor patients on aspirin therapy
experienced significantly lower gastrointestinal
complications when using a PPI for prophylaxis
7. Which of the following statements is incorrect?
a. The active metabolite for ticagrelor binds
reversibly to the P2Y12 receptor
b. Clopidogrel requires dose adjustment for hepatic
impairment
c. Inter-patient genetic variability has less effect on
prasugrel than clopidogrel.
d. All of the above statements are correct

8. Which of the following statements is correct
regarding platelet inhibition?
a. Clopidogrel has a faster platelet inhibition time
than prasugrel but slower than ticagrelor
b. All three drugs have similar platelet inhibition
times
c. Ticagrelor and prasugrel have faster platelet
inhibition times than clopidogrel
d. None of the above statements are correct
9. Which of the following is an appropriate
protocol for dosing prior to a CABG procedure?
a. Hold ticagrelor for 1 day prior to CABG
b. Hold prasugrel for 7 days prior to CABG
c. Hold clopidogrel for 2-3 days prior to CABG
d. All of the drugs should be held no longer than
1-2 days prior to CABG
10. 55 year-old, 50 kg patient is admitted for
STEMI, and is taken to the cardiac catherization
lab for primary PCI. The patient has a past medical
history of hypertension and a transient ischemic
attack in 2005. Her renal and hepatic function are
within normal limits. Current medications include
aspirin 325 mg daily, metoprolol 25 mg twice
daily, and atorvastatin 20 mg daily. Which of the
following is the BEST recommendation for antiplatelet therapy for this patient?
a. Clopidogrel 600 mg loading dose, then 75 mg
daily
b. Prasugrel 20mg mg loading dose, then 10 mg
daily
c. Prasugrel 60 mg loading dose, then 10 mg daily
d. Ticagrelor 180 mg loading dose, then 90 mg

twice daily

This activity was developed by
the Arizona Pharmacy Association
for pharmacists as a knowledgebased learning activity. The
Arizona Pharmacy Association is accredited by the
Accreditation Council for Pharmacy Education as a
provider of continuing pharmacy education.

Anti-platelet Therapy in Acute Coronary Syndromes: Updates in Therapy after Stent Implantation
ACPE UAN#0100-0000-12-069-H01-P						
This activity is accredited for 1.0 hours of CPE credit (CEUs 0.10)			
This activity is a benefit to AzPA members. Non-members of AzPA must enclose a $25.00 check payable to the Arizona Pharmacy Association.
In order to qualify for ACPE credit, participants must achieve a grade of 70% or above on the quiz and submit a completed activity evaluation.		
ACTIVITY EVALUATION – Please indicate if the activity met the stated learning objectives:
1. Identify the mechanism of action and unique characteristics of the FDA-approved P2Y12 receptor antagonists used in
secondary prevention of cardiovascular disease.								
2. Describe the recent recommendations regarding safety and efficacy for oral anti-platelet therapy post cardiacstent placement. 											
3. Compare the benefits and risks associated with each P2Y12 receptor antagonists based on presented clinical data. 		
4. Select the appropriate anti-platelet therapy using patient-specific parameters for prevention of recurrent cardiac events. 		
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AGREE
AGREE
AGREE

DISAGREE.
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DISAGREE
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1

2

3

4

5
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